Bayer bolsters birth-control business with $1.1B Conceptus buyout

Tracy Staton What's a birth-control drug maker to do when its pills start to flag? Turn to a device instead. That's the strategy Bayer is using to bolster its contraceptives ...

Elan spurns buyout offer, preps for deal spree

John Carroll Elan's ($ ELN) board of directors has rejected an $ 11.25-per-share bid by Royalty Pharma, sending a message along that it views the offer as far short of what the ...

Russia tells Abbott no-go on buyout of partner Petrovax

Eric Palmer Russia is one of the emerging BRIC countries that Big Pharma sees as the key to growth. It has a growing middle class, petro dollars to spend and a desire for better pharmaceutical ...

Elan investors approve share buy-back but still must decide on buyout

Eric Palmer Being a shareholder in Elan these days is a bit like taking a multiple choice quiz in an advanced MBA class.  They have just resoundingly approved a buy-back plan ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS